Novo Nordisk has inked a research collaboration potentially worth $550 million with Replicate Bioscience to develop next-generation metabolic drugs using self-replicating RNA (srRNA) technology. The deal provides Novo exclusive global rights to Replicate’s srRNA platform to target cardiometabolic diseases like obesity and type 2 diabetes. This partnership reflects Novo’s strategic expansion into cutting-edge RNA modalities following previous acquisitions to strengthen its drug development pipeline amid leadership transitions.